The present invention relates to compounds effective for the modulation of members of the protein kinase C (PKC) enzymatic family, including but not limited to, protein kinase epsilon (PKCε) inhibitors, protein kinase beta II (PKCβII) inhibitors, protein kinase zeta (PKCζ) inhibitors, and protein kinase C delta (PKCδ) activators. The present disclosure also relates to the mitigation of reperfusion (R) injury following the restoration of blood flow to previously ischemic (I) tissue. The present disclosure additionally relates to conjugates of PKC modulator peptides and a transduction domain of Trans-Activator of Transcription (TAT), and lipidated adducts thereof. The present disclosure further relates to a method of improving the therapeutic efficacy and solubility of compounds and drugs via dual conjugation of TAT and lipid moieties such as, for example, myristoyl.

The invention provides a composition comprising SGEF protein or gene as a therapeutic means to clinical or subclinical defects associated with anomalies of at least one from among the macula, corpus callosum, hippocampus, liver or immune system and diseases including a feverless response to infection, a cancer or vision loss. Methods of diagnosis of such disease and development anomalies are based on detection of mutations of the SGEF gene or altered levels of the SGEF mRNA or protein. A change of at least about 20% in the level of expression visa-vie a normal individual indicates an SGEF anomaly. The SGEF protein is also used as a preventive or curative treatment of atherosclerosis by local or systemic delivery. The invention also provides a composition comprising an inhibitor of the SGEF gene expression or SGEF protein concentration, as a therapeutic means for glaucoma, osteoarthritis, auto-inflammatory diseases, tumors or cancers.

The present invention relates to compounds of Formula I which form hydrogels upon mixing with water, and to fibers which form from the compounds. The hydrogels and fibers are antibacterial and not toxic towards mammalian cells. Such compounds, hydrogels, and fibers are useful, for example, in the treatment of surfaces such as in dermal or internal wounds as a barrier layer, or any article which may require disinfection. (I)

##STR00001##

Disclosed are compounds and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods for improving platelet survival upon transfusion with one or more compounds or compositions as described herein.

Provided herein are organ preservation solutions and methods of use thereof for preserving organs. In particular, provided herein are preservation solutions comprising a mineralocorticoid receptor antagonist, aldehyde dehydrogenase agonist, and/or histone deacetylase inhibitor, and methods of perfusing and storing an organ while awaiting transplantation or non-transplant surgery.

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

This invention relates to the preservation of vascularized tissues and organs by freezing or by vitrification; to organ and tissue cryopreservation or banking; and to tissue and organ perfusion with cryoprotective agents (also known as cryoprotectants).

Provided are a vehicle body assembling method and a vehicle body assembling apparatus which allow a simple configuration in the vicinity of the connecting portion between an upper jig and a lower jig and allow an increase in the efficiency of assembling work (welding work). A vehicle body assembling apparatus is equipped with a jig for supporting vehicle body components in a preassembled position, the jig comprising an upper jig and a lower jig which are connected to each other in at least two places. Each of the connection places is provided with a connecting means for fixing a three-dimensional coordinate position while allowing uniaxial turning. The vehicle body assembling apparatus is also equipped with a conveying means for conveying the upper jig which supports the vehicle body components, and reduces the load applied to the lower jig from the upper jig when connecting the upper jig to the lower jig.

In one representative embodiment, a method of perfusing organs in a patient's body is provided. The method comprises isolating the visceral arteries and the visceral veins from blood circulating through the patient's heart and perfusing the visceral arteries, the visceral veins, and the abdominal organs with a perfusion fluid that is fluidly separated from the blood circulating through the patient's heart. While the visceral arteries and the visceral veins are isolated, and the visceral arteries, the visceral veins, and the abdominal organs are being perfused, the patient's blood is allowed to continue to circulate through the heart.

This disclosure is directed to nucleic acid and cell preservative compositions. Methods of preserving nucleic acids and/or cells in a blood or other biological sample, and kits for preserving nucleic acids and/or cells in a blood or other biological sample are also described.